SeaStar Medical (NASDAQ:ICU) Stock Price Up 1.2% – What’s Next?

Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) rose 1.2% on Wednesday . The company traded as high as $2.49 and last traded at $2.45. Approximately 58,936 shares traded hands during trading, a decline of 44% from the average daily volume of 104,651 shares. The stock had previously closed at $2.42.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Wall Street Zen raised SeaStar Medical to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of SeaStar Medical in a research note on Thursday, January 22nd. Finally, Maxim Group set a $6.00 price objective on shares of SeaStar Medical in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell” and a consensus price target of $6.00.

SeaStar Medical Stock Up 1.2%

The stock has a market capitalization of $9.29 million, a price-to-earnings ratio of -0.15 and a beta of -1.00. The stock’s 50-day simple moving average is $2.53 and its 200 day simple moving average is $5.07.

Institutional Trading of SeaStar Medical

A number of hedge funds and other institutional investors have recently made changes to their positions in ICU. Trinity Financial Advisors LLC lifted its position in SeaStar Medical by 233.3% during the 3rd quarter. Trinity Financial Advisors LLC now owns 50,000 shares of the company’s stock worth $28,000 after buying an additional 35,000 shares in the last quarter. XTX Topco Ltd grew its stake in shares of SeaStar Medical by 395.4% during the second quarter. XTX Topco Ltd now owns 60,983 shares of the company’s stock valued at $26,000 after purchasing an additional 48,674 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of SeaStar Medical in the fourth quarter valued at approximately $30,000. Finally, Millennium Management LLC acquired a new position in SeaStar Medical during the 3rd quarter worth $102,000. 1.69% of the stock is currently owned by institutional investors and hedge funds.

About SeaStar Medical

SeaStar Medical, Inc (NASDAQ: ICU) is a medical device company focused on the development and commercialization of cerebral embolic protection systems for patients undergoing transcatheter aortic valve replacement (TAVR) procedures. The company’s mission is to reduce the risk of stroke and other neurologic events associated with structural heart interventions by capturing or deflecting embolic debris that can travel to the brain during catheter-based therapies.

The company’s flagship product, TriGUARD® 3, is a next-generation embolic deflection device designed to provide coverage of all three cerebral vessels during TAVR.